Zimmer Holdings, Inc. Form 10-Q Summary
Business context and reporting period
This unaudited Form 10-Q covers Zimmer Holdings, Inc. and subsidiaries for the three and nine months ended September 30, 2010. The company designs, manufactures and markets orthopaedic reconstructive, dental, spine, trauma and surgical products in more than 100 countries through the Americas, Europe and Asia Pacific segments.
Financial performance and liquidity
| Metric | Q3 2010 | Q3 2009 | 9M 2010 | 9M 2009 |
|---|---|---|---|---|
| Net sales | $965.0 million | $975.6 million | $3,085.5 million | $2,988.1 million |
| Operating profit | $271.6 million | $204.0 million | $793.8 million | $780.3 million |
| Net earnings | $191.1 million | $149.9 million | $562.0 million | $562.2 million |
| Diluted EPS | $0.96 | $0.70 | $2.78 | $2.59 |
| Operating margin | 28.1% | 20.9% | 25.7% | 26.1% |
| Net margin | 19.8% | 15.4% | 18.2% | 18.8% |
| Operating cash flow | — | — | $852.5 million | $732.0 million |
Gross profit was $745.8 million in the third quarter and $2,347.3 million for the first nine months, representing margins of approximately 77.3% and 76.1%, respectively. Third-quarter cost of products sold declined to 22.7% of sales from 25.6%, reflecting improved manufacturing efficiency, better inventory management and unfavorable facility-related items in the prior-year period.
At September 30, 2010, cash and cash equivalents were $918.6 million, short-term investments were $63.0 million and total current assets were $3,007.3 million. Long-term debt was $1,138.6 million, with no short-term debt outstanding. The company had $139.8 million drawn under its $1.35 billion senior credit facility and $1,210.2 million of availability; it was in compliance with all covenants. Total liabilities were $2,181.8 million and stockholders’ equity was $5,821.9 million.
Investing cash outflows were $235.4 million for the nine months, while financing cash outflows were $390.6 million, including $404.6 million for repurchases of 7.1 million shares. Approximately $1.3 billion remained available under the $1.5 billion repurchase authorization. Management stated that operating cash flow and available borrowings were sufficient for working capital, capital expenditures and debt service.
Material changes versus prior comparable periods
- Third-quarter sales declined 1%, while nine-month sales increased 3%. Asia Pacific grew 12% in the quarter and 16% year to date; Europe declined 11% and 1%, respectively.
- Third-quarter operating profit increased 33% and net earnings increased 27%, primarily because of lower product costs, lower acquisition and realignment expenses, and no additional Durom Cup provision in the quarter.
- Nine-month operating profit increased 2%, but net earnings were essentially flat because higher interest expense and the $75.0 million Durom Cup provision offset operating improvement.
- Diluted EPS increased 37% in the quarter and 7% year to date, aided by substantial share repurchases and the resulting lower share count.
- Spine sales declined 9% in the quarter and 8% year to date, particularly in the Americas. Surgical and other sales increased 9% and 15%, respectively, partly recovering from prior product recall and production-suspension effects.
- Interest and other expense increased to $14.2 million in the quarter and $43.1 million year to date from $4.2 million and $11.9 million, respectively, due primarily to senior notes issued in November 2009.
- Operating cash flow increased $120.5 million year to date, while financing outflows increased because 2009 borrowings used to support repurchases were not repeated in 2010.
Guidance, outlook, commentary and risks
- Management expected global selling prices to decline approximately 1% to 2% for full-year 2010 because of healthcare cost-containment efforts and pricing pressure.
- Management expected foreign currency movements to provide an approximately 0% to 1% positive effect on full-year 2010 sales, with limited near-term earnings impact because of hedging.
- Research and development spending was expected to be 5% to 6% of full-year sales. Investment was being increased in product development, clinical, regulatory and quality initiatives.
- The company reported a total Durom Cup-related provision of $179.0 million and estimated remaining liability of $142.5 million at September 30, 2010, including $42.5 million current and $100.0 million long term. Management expected most payments within three years, but acknowledged that actual claims could differ materially from estimates.
- The U.S. Spine reporting unit remained subject to impairment risk. No interim impairment charge was recorded in 2010, but lower forecast cash flows, weaker revenue or margins, or higher discount rates could require future impairment.
- Material risk areas include competition, pricing and reimbursement pressure, economic and procedure-volume weakness, foreign exchange, product liability, regulatory and quality matters, intellectual property litigation, tax audits, the SEC and DOJ FCPA investigation, and compliance with the Corporate Integrity Agreement through 2012.
- The company had ongoing product liability, patent, securities, ERISA and governmental matters. Management stated that intellectual property claims were not expected to have a material adverse effect, but outcomes could not be predicted with certainty.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2010, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the ultimate cash cost and timing of Durom Cup claims relative to the $142.5 million remaining recorded liability.
- Monitor U.S. Spine revenue, margins, cash-flow forecasts and potential goodwill impairment.
- Assess whether the third-quarter slowdown in hospital procedure volumes and European weakness persists.
- Review pricing pressure, reimbursement changes, medical-device healthcare reform effects and the sustainability of gross-margin improvement.
- Track interest expense, debt maturities, credit-facility availability and continued share repurchases.
- Follow the SEC/DOJ FCPA investigation, Corporate Integrity Agreement compliance, tax audits and pending litigation.
- Note that the filing is for Zimmer Holdings, Inc. as of 2010; the provided request metadata identifies Zimmer Biomet, so the issuer name should be reconciled before use.